EyePoint Pharmaceuticals (STU:PV3B) Net Margin %

: -100.51% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. EyePoint Pharmaceuticals's Net Income for the three months ended in Dec. 2023 was €-12.93 Mil. EyePoint Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €12.86 Mil. Therefore, EyePoint Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was -100.51%.

The historical rank and industry rank for EyePoint Pharmaceuticals's Net Margin % or its related term are showing as below:

STU:PV3B' s Net Margin % Range Over the Past 10 Years
Min: -1795.71 Med: -246.08 Max: 23.89
Current: -153.84

STU:PV3B's Net Margin % is ranked better than
51.07% of 1026 companies
in the Biotechnology industry
Industry Median: -163.08 vs STU:PV3B: -153.84

EyePoint Pharmaceuticals Net Margin % Historical Data

The historical data trend for EyePoint Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-278.87

-131.82

-158.14

-246.97

-153.84

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-412.54	-275.46	-251.73	-82.96	-100.51

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Net Margin % falls into.

EyePoint Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

EyePoint Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-64.919	/	42.199
	=	-153.84 %

EyePoint Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-12.929	/	12.864
	=	-100.51 %

EyePoint Pharmaceuticals (STU:PV3B) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

EyePoint Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines